Health Care
Adalta Limited (1AD)
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.
Market Cap
A$9M
Shares on Issue
N/A
Price Chart
AI Analysis
As a speculative, clinical-stage biotechnology company with a market cap of A$11M, Adalta's value is intrinsically tied to the potential of its intellectual property and clinical progress. The company is pre-revenue and therefore reliant on investor capital to fund its research and development, particularly the advancement of its lead candidate, AD-214. Its financial performance is characterized by R&D expenditure and periodic capital raisings, making cash runway a key operational metric.
Adalta's growth outlook is wholly dependent on successful clinical trial outcomes and strategic partnerships. The primary catalyst is positive data from its AD-214 trials, which would significantly de-risk the asset and attract potential licensing partners. A successful partnership with a major pharmaceutical company would provide crucial non-dilutive funding and external validation of its i-body platform, potentially leading to a substantial re-evaluation of the company.
Bull Case
- • Positive clinical trial data for lead candidate AD-214 would be a major de-risking event and could cause a significant share price re-rating.
- • Securing a licensing deal or partnership with a large pharmaceutical company would validate the i-body platform and provide a clear path to commercialisation.
- • The underlying i-body platform technology could be applied to develop a pipeline of candidates for other high-value diseases, creating long-term value.
Bear Case
- • Clinical trial failure for AD-214 would be a major setback, as the company's valuation is heavily dependent on this single lead asset.
- • As a pre-revenue company, Adalta faces significant funding risk and will likely require further capital raises, leading to potential dilution for existing shareholders.
- • The therapeutic area for fibrosis is highly competitive, with larger, better-funded companies also developing treatments, posing a significant competitive threat.
Recent Announcements
AdCella expands clinical advisory board
🚨 Price SensitiveAdCella expands clinical advisory board
AdCella Clinical Advisory Board convened
🚨 Price SensitiveAdCella Clinical Advisory Board convened
Half Yearly Report and Accounts
🚨 Price SensitiveHalf Yearly Report and Accounts
New AD-214 patent granted
🚨 Price SensitiveNew AD-214 patent granted
Fadi Diab to join AdAlta Board
FAQs
What does 1AD do?
Adalta (1AD) is a biotechnology company developing a new class of drugs called i-bodies to treat inflammatory and fibrotic diseases. Its lead drug candidate is AD-214.
Is 1AD profitable?
No, like most clinical-stage biotechnology companies, Adalta is not yet profitable as it invests heavily in research and development and has no commercial revenue.
What drives 1AD's share price?
The share price is primarily driven by news on its clinical trials, capital raising activities, and announcements regarding potential commercial partnerships or licensing deals.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$138.50
-44.8% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.91
-24.8% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1AIAlgorae Pharmaceuticals Limited
A$0.01
150.0% 1Y
Algorae Pharmaceuticals is an Australian drug discovery company utilizing its proprietary artificial intelligence platform, AlgoraeOS, to identify and develop novel therapeutic treatments. The company focuses on creating drug candidates for conditions with unmet medical needs, including dementia, cardiovascular disease, and Meniere's disease. Its business model is centered on leveraging AI to accelerate the traditionally lengthy and costly process of pharmaceutical research and development.